Eli Lilly announced positive top-line Phase 3 results from its ACHIEVE-1 trial for orforglipron in adults with type 2 diabetes on April 17, 2025. The investigational once-daily oral GLP-1 pill successfully achieved its primary and key secondary endpoints. This marks a significant step forward for Eli Lilly in the oral incretin market.
The data indicated that orforglipron demonstrated similar efficacy and safety relative to weekly injectable semaglutide, a leading GLP-1 receptor agonist. This outcome reinforces the potential for oral therapies to compete effectively with injectable treatments in managing type 2 diabetes and related metabolic conditions.
For Viking Therapeutics, this development from a major competitor validates the market for oral GLP-1/GIP agonists but also intensifies the competitive landscape. It establishes a high benchmark for efficacy and tolerability that Viking's own oral VK2735 will need to meet or exceed to differentiate itself in the market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.